Correction to: Dexamethasone-induced cisplatin and gemcitabine resistance in lung carcinoma samples treated ex vivo
- PMID: 37723318
- PMCID: PMC10575916
- DOI: 10.1038/s41416-023-02433-5
Correction to: Dexamethasone-induced cisplatin and gemcitabine resistance in lung carcinoma samples treated ex vivo
Erratum for
-
Dexamethasone-induced cisplatin and gemcitabine resistance in lung carcinoma samples treated ex vivo.Br J Cancer. 2005 Mar 28;92(6):1084-8. doi: 10.1038/sj.bjc.6602453. Br J Cancer. 2005. PMID: 15756274 Free PMC article.
Similar articles
-
Dexamethasone-induced cisplatin and gemcitabine resistance in lung carcinoma samples treated ex vivo.Br J Cancer. 2005 Mar 28;92(6):1084-8. doi: 10.1038/sj.bjc.6602453. Br J Cancer. 2005. PMID: 15756274 Free PMC article.
-
Palonosetron with aprepitant plus dexamethasone to prevent chemotherapy-induced nausea and vomiting during gemcitabine/cisplatin in urothelial cancer patients.Int J Urol. 2015 Oct;22(10):911-4. doi: 10.1111/iju.12842. Epub 2015 Jun 18. Int J Urol. 2015. PMID: 26087891
-
Gemcitabine inhibits cisplatin resistance in cisplatin-resistant A549 cells by upregulating trx-interacting protein and inducing cell cycle arrest.Biochem Biophys Res Commun. 2020 Apr 9;524(3):549-554. doi: 10.1016/j.bbrc.2020.01.130. Epub 2020 Jan 31. Biochem Biophys Res Commun. 2020. PMID: 32014255
-
Influence of genetic markers on survival in non-small cell lung cancer.Drugs Today (Barc). 2003 Oct;39(10):775-86. doi: 10.1358/dot.2003.39.10.799471. Drugs Today (Barc). 2003. PMID: 14668933 Review.
-
Targeted therapy in combination with gemcitabine in non-small cell lung cancer.Semin Oncol. 2003 Aug;30(4 Suppl 10):19-25. doi: 10.1016/s0093-7754(03)00281-1. Semin Oncol. 2003. PMID: 12917817 Review.
References
Publication types
LinkOut - more resources
Full Text Sources